07/01/2025
6:40 AM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form ARS | |
07/01/2025
6:30 AM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form DEF 14A | |
07/01/2025
6:35 AM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form DEFA14A | |
06/20/2025
6:20 AM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/15/2025
1:06 PM | EcoR1 Capital, LLC (Filed by)
Kalaris Therapeutics, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
05/14/2025
7:09 AM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/16/2025
3:18 PM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/11/2025
4:04 PM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
PATEL SAMIR CHANDRAKANT (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/11/2025
4:08 PM | Jovan-Embiricos Morana (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/11/2025
4:20 PM | AKKARAJU SRINIVAS (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/11/2025
4:27 PM | Hagen Brett R (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for KLRS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Kalaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
04/11/2025
4:03 PM | Ferrara Napoleone (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/11/2025
3:41 PM | Hallal David (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/04/2025
7:21 AM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
PATTERSON LEONE D (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
04/04/2025
7:12 AM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/27/2025
6:19 PM | Hagen Brett R (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/26/2025
4:06 PM | AKKARAJU SRINIVAS (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 3/A | |
03/25/2025
6:38 PM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Samsara BioCapital GP, LLC (Reporting)
Samsara BioCapital, L.P. (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/25/2025
6:40 PM | Kalaris Therapeutics, Inc. (Subject)
Kalaris Therapeutics (Subject)
Samsara BioCapital, L.P. (Filed by)
| Form SCHEDULE 13D | |
03/20/2025
3:32 PM | GILEAD SCIENCES, INC. (Filed by)
Kalaris Therapeutics, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
03/18/2025
4:44 PM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
PATEL SAMIR CHANDRAKANT (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
4:45 PM | Ferrara Napoleone (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
4:37 PM | ADAMIS ANTHONY P (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
4:40 PM | AKKARAJU SRINIVAS (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
4:41 PM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Oxtoby Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
4:43 PM | Feinsod Matthew (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
4:25 PM | Dybbs Michael (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:27 PM | Ferrara Napoleone (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:30 PM | AKKARAJU SRINIVAS (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:14 PM | ADAMIS ANTHONY P (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:17 PM | Feinsod Matthew (Reporting)
Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:20 PM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Oxtoby Andrew (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:21 PM | Kalaris Therapeutics, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
PATEL SAMIR CHANDRAKANT (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/18/2025
4:04 PM | Kalaris Therapeutics, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/12/2025
3:18 PM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/07/2025
6:30 AM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/24/2025
10:51 AM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/24/2025
10:55 AM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/24/2025
10:56 AM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/14/2025
12:17 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
EcoR1 Capital, LLC (Filed by)
| Form SCHEDULE 13G/A | |
02/10/2025
11:15 PM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form EFFECT | |
The Coin That Could Define Trump’s Crypto Presidency (Ad) When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed.
While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.” Discover the coin that could define Trump’s crypto presidency. |
02/10/2025
3:19 PM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 424B3 | |
01/24/2025
1:51 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/24/2025
1:55 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/24/2025
2:03 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/15/2025
3:39 PM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/15/2025
3:41 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
01/13/2025
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Sinha Vikas (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/13/2025
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Hagen Brett R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/13/2025
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Miller Edward (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/10/2025
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2025
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2025
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2025
6:44 AM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
01/10/2025
6:42 AM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/20/2024
3:21 PM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/20/2024
3:23 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
12/11/2024
4:07 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Miller Edward (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
5:37 AM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form S-4
Registration statement under Securities Act of 1933 | |
12/06/2024
8:50 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
12/06/2024
6:23 AM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form DEF 14A | |
11/20/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Brainard Diana (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/20/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Miller Edward (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/20/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Sinha Vikas (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/20/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Hagen Brett R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/19/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/19/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Brainard Diana (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/19/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/19/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/08/2024
3:05 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
11/08/2024
3:06 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
11/08/2024
3:09 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
11/08/2024
3:10 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
11/08/2024
7:26 AM | Allovir, Inc. (Filer)
Kalaris Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/08/2024
7:33 AM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
| Form 425 | |
11/05/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/05/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/05/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/05/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Brainard Diana (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Miller Edward (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/23/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Hagen Brett R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/23/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Sinha Vikas (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/23/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Brainard Diana (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/22/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/22/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Brainard Diana (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/21/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/04/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Hagen Brett R (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Amazon’s big Bitcoin embarrassment (Ad) Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity.
While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video. Watch the Bitcoin Skimming strategy here |
10/04/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Brainard Diana (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/04/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Miller Edward (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/04/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Sinha Vikas (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Miller Edward (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/03/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Sinha Vikas (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/03/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Hagen Brett R (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/03/2024
7:00 PM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Brainard Diana (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/22/2024
3:15 PM | Allovir, Inc. (Issuer)
Kalaris Therapeutics (Issuer)
Brainard Diana (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
10:14 AM | Allovir, Inc. (Subject)
Kalaris Therapeutics (Subject)
Brainard Diana (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
